The Sydney Melanoma Unit - A multidisciplinary melanoma treatment center

Surgical Clinics of North America

Volumn 83, Issue 2, 2003, Pages 431-451

  Thompson, John F ^a   Shaw, Helen M ^b   Stretch, Jonathan R ^b   McCarthy, William H ^b   Milton, Gerald W ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER CENTER; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DATA BASE; FOLLOW UP; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; LIMB PERFUSION; LYMPH NODE DISSECTION; MELANOMA; MULTIMODALITY CANCER THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY;

AUSTRALIA; CANCER CARE FACILITIES; DATABASES, FACTUAL; GOVERNMENT PROGRAMS; HISTORY, 20TH CENTURY; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MELANOMA; NEW SOUTH WALES; PALLIATIVE CARE; POPULATION SURVEILLANCE; PORTRAITS; SKIN NEOPLASMS;

EID: 0037396420     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00090-7     Document Type: Review

References (49)

1. Lancaster HO, Nelson J. Sunlight as a cause of melanoma: a clinical survey. Med J Aust 1957;1:452-6.
2. Milton GW, Lewis CWD. The presentation of malignant melanoma (melanoblastoma). Med J Aust 1963;1:239-42.
3. McGovern VJ. Melanoma: growth patterns, multiplicity and regression. In: McCarthy WH, editor. Melanoma and skin cancer. Sydney: Blight NSW Government Printer; 1972. p. 95-106.
4. McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973;32:1446-57.
5. McGovern VJ, Shaw HM, Milton GW, et al. Prognostic significance of the histological features of malignant melanoma. Histopathology 1979;3:385-93.
6. Thompson JF, Hunt JA, Shannon KF, et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-8.
7. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high risk melanoma using vaccinia viral lysates of melanoma. Results of a randomized trial. J Clin Oncol 2002;20:4181-90.
8. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906-12.
9. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg 1999;230:453-65.
10. Urist MM, Balch CM, Soong SJ, et al. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55:1398-402.
11. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma Unit from 1960 to 1991. J Am Coll Surg 1995;180:402-9.
12. McCarthy WH, Shaw HM, Cascinelli N, et al. Elective lymph node dissection: two perspectives. World J Surg 1992;16:203-13.
13. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982;69:108-11.
14. O'Brien CJ, Coates AS, Petersen-Schaeffer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991;162:310-4.
15. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128-35.
16. La Hei ER, Thompson JF, McCaughan BC, et al. Surgical resection of pulmonary metastatic melanoma. A review of 83 thoracotomies. Asian Pac J Thorac Cardiovasc Surg 1996;5:111-4.
17. Zacest AC, Besser M, Stevens G, et al. Surgical management of cerebral metastases for melanoma: outcome of 147 patients treated at a single institution over two decades. J Neurosurg 2002;96:552-8.
18. Balch CM, Milton GW, Shaw HM, et al. editors. Cutaneous melanoma. 1st edition Philadelphia: Lippincott; 1985.
19. Menzies SW, Ingvar C, McCarthy WH. An atlas of surface microscopy of pigmented skin lesions. Sydney: McGraw-Hill; 1996.
20. Holland EA, Schmid H, Kefford RF, et al. CDKN2A (p16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999;25:339-48.
21. Kefford RF, Newton Bishop JA, Bergman W, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.
22. O'Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589-94.
23. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000;88:87-94.
24. Hersey P, Edwards A, Coates A, et al. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patient with stage II melanoma. Cancer Immunol Immunother 1987;25:257-65.
25. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
26. Creech O, Krementz ET, Ryan Rf, et al. Chemotherapy of cancer - regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
27. Thompson JF, Kam PCA, Waugh RC, et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47.
28. Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994;7:188-92.
29. Lindner P, Doubrovsky A, Kam P, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36.
30. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992;127:392-9.
31. Uren RF, Howman-Giles RB, Shaw HM, et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting drainage node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993;34:1435-40.
32. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg 1999;189:195-206.
33. Uren RF, Thompson JF, Howman-Giles RB. Lymphatic drainage of the skin and breast. Amsterdam: Harwood Academic Publishers; 1999.
34. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
35. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
36. Milton GW. The site and time of recurrence of malignant melanoma. Med J Aust 1966;1:283-7.
37. Milton GW, Shaw HM, Farago GA, et al. Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I). Br J Surg 1980;67:543-6.
38. Balch CM, Milton GW. Diagnosis of metastatic melanoma at distant sites. In: Balch CM, Milton GW, Shaw HM, et al. editors. Cutaneous melanoma. 1st edition. Philadelphia: Lippincott; 1985. p. 221-250.
39. McCarthy WH, Shaw HM, Thompson JF, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
40. Ruark DS, Shaw HM, Ingvar C, et al. Who detects the first recurrence in stage I cutaneous malignant melanoma: patient or doctor? Melanoma Res 1993;3:44.
41. Poo-Hwu W-J, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stage I-III malignant melanoma. Cancer 1999;86:2252-8.
42. Mooney MM, Mettlin C, Michalek AM, et al. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997;80:1052-64.
43. Morton DL, Giuliano AE, Reintgen DS, et al. Lymphatic mapping and sentinel node biopsy in patients with breast cancer and melanoma (II). Contemp Surg 1998;53:353-61.
44. Cochran AJ, Starz H. Pathologic aspects. In: Cody HS III, editor. Sentinel lymph node biopsy. London: Martin Dunitz; 2002. p. 79-90.
45. Solomon MJ, McLeod RS. Should we be performing more randomized controlled trials evaluating surgical operations? Surgery 1995;118:459-67.
46. Solomon MJ, Thomas RJ, Gattellari M, et al. Does type of surgeon matter in rectal cancer surgery? Evidence, guideline consensus and surgeons' views. Aust NZ J Surg 2001;71:711-4.
47. Thiemann DR, Coresh J, Oetgen WJ, et al. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med 1999;340:1640-8.
48. Expert Advisory Group on Cancer. A policy framework for commissioning cancer services. London: Department of Health; 1995.
49. National Health and Medical Research Council. (NH&MRC). Clinical practice guidelines for the management of cutaneous melanoma. 1999. Available at: http://www.health.gov.au:80/nhmrc/publications/synopses/cp68syn.htm.